Rakuten Securities Inc. Invests $126,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Rakuten Securities Inc. purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 805 shares of the company’s stock, valued at approximately $126,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Entropy Technologies LP raised its stake in TransMedics Group by 34.7% in the third quarter. Entropy Technologies LP now owns 10,471 shares of the company’s stock valued at $1,644,000 after buying an additional 2,700 shares during the period. WCM Investment Management LLC acquired a new position in shares of TransMedics Group during the 3rd quarter worth approximately $8,720,000. Venturi Wealth Management LLC raised its stake in TransMedics Group by 33.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock valued at $136,000 after acquiring an additional 219 shares during the period. Jag Capital Management LLC acquired a new stake in TransMedics Group during the 3rd quarter valued at $208,000. Finally, Chartwell Investment Partners LLC bought a new position in TransMedics Group during the third quarter worth $662,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insider Buying and Selling at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the transaction, the insider now owns 21,105 shares of the company’s stock, valued at $3,714,902.10. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,958 shares of company stock valued at $5,230,528. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $89.11 on Tuesday. The stock has a market capitalization of $2.99 billion, a PE ratio of 94.80 and a beta of 2.08. TransMedics Group, Inc. has a fifty-two week low of $56.83 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The business has a fifty day moving average price of $130.45 and a two-hundred day moving average price of $139.89.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.12) EPS. As a group, equities analysts predict that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research reports. Morgan Stanley raised their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. JPMorgan Chase & Co. reduced their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. Robert W. Baird decreased their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Piper Sandler reissued an “overweight” rating and set a $180.00 price target on shares of TransMedics Group in a report on Tuesday, October 29th. Finally, Oppenheimer decreased their price objective on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.